243,427 Shares of Boston Scientific Corporation $BSX Bought by International Assets Investment Management LLC

International Assets Investment Management LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 243,427 shares of the medical equipment provider’s stock, valued at approximately $10,626,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $5,534,781,000. Primecap Management Co. CA purchased a new position in shares of Boston Scientific during the 2nd quarter worth approximately $2,156,233,000. Janus Henderson Group PLC raised its position in shares of Boston Scientific by 31.0% during the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after purchasing an additional 3,907,981 shares during the last quarter. Amundi raised its position in shares of Boston Scientific by 13.8% during the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock worth $886,213,000 after purchasing an additional 1,707,754 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Boston Scientific by 25.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after purchasing an additional 2,856,040 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

Boston Scientific Stock Down 1.8%

Shares of NYSE BSX opened at $41.93 on Friday. The firm has a market cap of $60.77 billion, a P/E ratio of 17.77, a price-to-earnings-growth ratio of 1.03 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a 1 year low of $39.57 and a 1 year high of $105.65. The firm’s 50 day moving average price is $44.78 and its 200 day moving average price is $56.88.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. Boston Scientific had a return on equity of 18.73% and a net margin of 16.62%. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the previous year, the firm posted $0.75 EPS. Boston Scientific’s revenue was up 1.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

Insiders Place Their Bets

In other Boston Scientific news, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 189,522 shares of company stock valued at $9,157,810. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Leerink Partners lowered their target price on Boston Scientific from $55.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday. Royal Bank Of Canada dropped their price target on Boston Scientific from $70.00 to $52.00 and set an “outperform” rating for the company in a research report on Thursday. JPMorgan Chase & Co. cut Boston Scientific from an “overweight” rating to a “neutral” rating and set a $46.00 price target for the company. in a report on Wednesday. Canaccord Genuity Group reduced their price objective on Boston Scientific from $66.00 to $48.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Jefferies Financial Group downgraded Boston Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the company from $60.00 to $46.00 in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.43.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.